BioSpace News Archive

AbbVie announced the creation of a new global business, Allergan Aesthetics, an AbbVie company, and the proposed leadership team for the combined company, effective upon the expected first-quarter 2020 close of the Allergan acquisition.

Birmingham, Ala.-based Encompass Health Corp. and San Angelo, Texas-based Shannon Health announced plans to form a joint venture for a new, 40-bed, freestanding inpatient rehabilitation hospital in San Angelo, Texas.

Transcenta Holding Limited (“Transcenta”), a global biotherapeutics company with fully-integrated capabilities in discovery, R&D, and manufacturing of antibody-based therapeutics, announces today that it has sealed a 100 million USD series B+ round.

Event rallying rare disease innovators, investors, and patients, coinciding with J.P. Morgan’s annual healthcare conference

ArcherDX, Inc., a molecular diagnostics company dedicated to developing breakthrough solutions that advance the application of personalized genomic medicine, today announced that Jason Myers, Ph.D., Chief Executive Officer, will present an overview of the company and its products at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco, California.

Inhibrx, Inc. (Inhibrx), a clinical-stage biotechnology company with a broad pipeline of biotherapeutics in development, announced today the administration of the first dose of INBRX-106 in a Phase 1 dose-escalation clinical study.

Colospan which develops novel solutions for colorectal surgery, announced today that the United States Food and Drug Administration (FDA) has approved the company’s investigational device exemption (IDE) application.

Knight Therapeutics Inc., a pan-American specialty pharmaceutical company and Debiopharm, a Swiss-based, global biopharmaceutical company, announced that they have entered into an exclusive agreement that grants Knight the rights to commercialize Trelstar® in Canada.

Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced independent centrally reviewed top-line data for pralsetinib in patients with RET fusion-positive non-small cell lung cancer (NSCLC).

Entrada Therapeutics, Inc. a biotechnology company dedicated to transforming the treatment of devastating diseases through the intracellular delivery of biologics, today announced that it is developing ENTR-501, a novel thymidine phosphorylase enzyme replacement therapy, for the treatment of mitochondrial neurogastrointestinal encephalomyopathy (MNGIE).